Abrégé

[Problem] To provide a novel technology. [Solution] One aspect of the present invention provides an information processing system. This information processing system comprises at least one processor, and the processor is configured to execute each of the following steps by reading a program. In a reception step, input information is received. The input information includes at least one of first input information related to the number of individuals infected with a specific infectious disease and second input information related to weather. In an output step, output information related to the risk of outbreak of the infectious disease is output on the basis of the input information and preset reference information.

Classes IPC  ?

• G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe

Abrégé

Provided are a system and a cardiopulmonary resuscitation device that primarily assist with smooth execution of tracheal intubation even during cardiopulmonary resuscitation.　A cardiopulmonary resuscitation device according to the present invention comprises an intubation arm, an imaging unit, a tube, an image processing control unit, and a drive control unit. The intubation arm comprises a flap part. The imaging unit is attached to the intubation arm. The image processing control unit comprises an epiglottis recognition unit and an insertion position determination unit. The drive control unit comprises a flap control unit and a tube contol unit. The epiglottis recognition unit recognizes at least a partial region of an epiglottis in an image or video imaged by the imaging unit. The insertion position determination unit recognizes a glottis region in the image or video and determines an insertion reference position for the tube on the basis of the recognized glottis region. The flap control unit controls the flap part so as to open the recognized epiglottis. The tube control unit controls the insertion of the tube on the basis of the tube insertion reference position.

Classes IPC  ?

• A61M 16/04 - Tubes trachéaux
• A61B 1/045 - Leur commande
• A61B 1/267 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments pour les voies respiratoires, p. ex. laryngoscopes, bronchoscopes

Abrégé

[Problem] To provide continuous assistance for treatment suitable for the state of a user. [Solution] A health assistance server disclosed in the present specification assists in maintenance or promotion of the health of a user. This health assistance server is characterized by comprising: an execution status acquisition unit that acquires a measurement value measured during execution of an action to be undertaken by the user; a range setting unit that receives the setting of a predetermined range according to the symptoms of the user with respect to the measurement value measured during execution of the action; and a reward granting unit that grants a reward to the user when the action has been executed, the reward granting unit granting different rewards to the user depending on whether the measurement value falls within the aforementioned range.

Classes IPC  ?

• G16H 20/00 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients

Abrégé

The patient information processing method includes a step of obtaining a plurality of pieces of vital data of a patient, a step of obtaining information indicating a content and a time of a treatment performed on the patient, and a step of causing a display to display information indicating at least one of the plurality of pieces of vital data or an index associated with the plurality of pieces of vital data, and to display information indicating the content and the time of the treatment.

Classes IPC  ?

• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

Provided are a resin composition for a medical simulator and a molded product thereof with improved visibility of a blood vessel in training for ultrasound diagnosis.　This resin composition for a medical simulator comprises a curable resin and an organic fiber.

Classes IPC  ?

• G09B 9/00 - Simulateurs pour l'enseignement ou l'entraînement
• G09B 23/28 - Modèles à usage scientifique, médical ou mathématique, p. ex. dispositif en vraie grandeur pour la démonstration pour la médecine
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores

Abrégé

An endoscopic treatment portion traction member is gripped by forceps to be inserted into an endoscope and then inserted into a body, and is fixed to a tissue to be resected and pulls the tissue from a surrounding tissue. The endoscopic treatment portion traction member includes: an annular body; and, an outer tongue provided in a peripheral portion of the annular body and is gripped by forceps.

Classes IPC  ?

• A61B 17/29 - Pinces pour la chirurgie faiblement invasive

Abrégé

The present invention relates to a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. In the formula (1), R1 to R3 are each independently a predetermined amino group or a predetermined amide group, or a group represented by the formula (2), and at least one of R1 to R3 is a group represented by the formula (2). The present invention relates to a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. In the formula (1), R1 to R3 are each independently a predetermined amino group or a predetermined amide group, or a group represented by the formula (2), and at least one of R1 to R3 is a group represented by the formula (2).

Classes IPC  ?

• A61K 49/04 - Préparations de contraste pour rayons X
• C07H 15/18 - Radicaux acycliques substitués par des carbocycles

Abrégé

The purpose of the present invention is to provide a novel detection method for chronic active Epstein-Barr virus (CAEBV) and a novel therapeutic pharmaceutical composition for CAEBV. The present invention provides a detection method for CAEBV that includes a step for measuring the amount or concentration of Flt3-L in a biological sample from a subject. The present invention also provides a therapeutic pharmaceutical composition for CAEBV that includes an Flt3 inhibitor. The present invention is advantageous for simply and accurately detecting CAEBV. The present invention is also advantageous for providing a novel therapeutic agent for CAEBV that targets Flt3.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12Q 1/6813 - Tests d’hybridation
• C12Q 1/6851 - Amplification quantitative
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]
• C12Q 1/6869 - Méthodes de séquençage

Abrégé

An inlet passage portion, which is a substantially columnar space through which a tip end of a guide wire is inserted into an opening portion to pass the guide wire, a shaping portion, which is a space communicating with the inlet passage portion through an outlet portion, which is a portion located at a deepest part of the inlet passage portion, and flatly expanding from the outlet portion, an annular inner wall, which forms an inner circumferential portion of the shaping portion, an extension line intersection portion, which is an inner wall intersecting an extension line of a center line of the inlet passage portion at an obtuse angle, and an obtuse angle side inner wall portion, which is an inner wall extending from the outlet portion to the extension line intersection portion and forming an obtuse angle with the extension line are included.

Classes IPC  ?

• A61M 25/09 - Fils de guidage
• A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques

Abrégé

The present invention pertains to a therapeutic or prophylactic for HTLV-1-associated myelopathy (HAM), said therapeutic or prophylactic including a substance that inhibit the activity of the MAPK signaling pathway in which mitogen-activated protein kinase kinase kinase 8 (MAP3K8) is involved.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

To provide a guide wire shaping mold that reduces damage to a blood vessel by folding back a tip end of the guide wire and do not require heating treatment, and a guide wire shaping method using the guide wire shaping mold. A guide wire shaping mold configured to shaping by reducing an annular diameter of the guide wire in which a tip end is annularly arranged, the guide wire shaping mold includes a wire shaping portion configured such that an annular portion of the guide wire is arranged, and a wire drawing path formed in a passage way shape, communicating with the wire shaping portion, and configured to retract the guide wire in a linear direction and in a base end direction.

Classes IPC  ?

• B21C 3/02 - MatricesEmploi d'un matériau spécifié pour ces filièresNettoyage de ces filières
• A61M 25/00 - CathétersSondes creuses
• A61M 25/09 - Fils de guidage
• B21C 3/04 - MatricesEmploi d'un matériau spécifié pour ces filièresNettoyage de ces filières à ouverture constante
• B21F 1/06 - Cintrage en forme annulaire, p. ex. pour former des œillets
• B21F 45/00 - Travail du fil métallique pour la fabrication d'autres objets particuliers
• B29C 33/38 - Moules ou noyauxLeurs détails ou accessoires caractérisés par la matière ou le procédé de fabrication
• B29C 53/02 - Cintrage ou pliage
• B29C 53/80 - Éléments constitutifs, détails ou accessoiresOpérations auxiliaires
• B29C 53/82 - Noyaux ou mandrins

Abrégé

[Problem] To provide an information processing system that prevents a decrease in QOL when an anomaly has occurred. [Solution] According to an aspect of the present invention, an information processing system is provided. The information processing system is configured to perform an acquiring step, a determining step, a calculating step, and a notifying step. In the acquiring step, an RR interval is acquired from detected pulses. In the determining step, it is determined whether the RR interval is smaller than the previous RR interval. In the calculating step, an interval difference between a first RR interval and an Nth RR interval is calculated in a period in which a determination of being smaller has been made in the determining step. N is an integer greater than or equal to 2. In the notifying step, if the interval difference is greater than or equal to a threshold value, an anomaly notification is made.

Classes IPC  ?

• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

[Problem to be Solved] Provided is a motile cell sorting device that can effectively sort motile cells, such as sperms, having excellent motility and morphology by performing image analysis when animal cells are sorted. [Means for Solution] The motile cell sorting device 1 comprises a storage unit 3, a first introduction unit (cell injection channel) 5, a first introduction control unit 7, a first holding unit (cell capture area) 9, a first derivation unit (cell collection channel) 11, a first derivation control unit 13, a collection unit (liquid storage) 15, a photographing unit 17, and a first controller 19.

Classes IPC  ?

• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
• C12M 1/26 - Inoculateur ou échantillonneur
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12Q 1/24 - Méthodes d'échantillonnage, d'inoculation ou de développement d'un échantillonMéthodes pour isoler physiquement un micro-organisme intact
• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

In order to improve a traction member that assists with lifting tissue to be excised from surrounding tissue and excising the tissue to be excised when performing treatment using an endoscope, the present invention provides a treatment part traction member for an endoscope in which the ease of gripping of the traction member by forceps for use in an endoscope and the ease of manipulation in a treatment area are improved. The treatment part traction member for an endoscope is gripped by forceps to be inserted into an endoscope, is inserted into a body and fixed to tissue to be excised, and pulls the tissue to be excised from surrounding tissue. The treatment part traction member for an endoscope is formed from an elastic resin and comprises an annular section and an outer tongue piece that is provided to one or two locations on the outer circumferential section of the annular section and gripped by the forceps.

Classes IPC  ?

• A61B 17/02 - Instruments, dispositifs ou procédés chirurgicaux pour maintenir les blessures ouvertes, p. ex. rétracteursÉcarteurs

Abrégé

The present invention is intended to provide a method for determining the prognosis of a hormone receptor-positive cancer (for example, an ERα-positive breast cancer, an ERα-positive endometrial cancer, etc.) or a method for assisting the determination of the prognosis, and a method for evaluating the sensitivity of the cancer to antihormone therapy or a method for assisting the evaluation of the sensitivity of the cancer to antihormone therapy. Specifically, the present invention relates to a method for determining the prognosis of a hormone receptor-positive cancer, or a method for assisting the determination of the prognosis, which comprises the following steps (a) and (b): (a) a step of detecting Fbxo22-positive cancer cells in a sample derived from the cancer tissues; and (b) a step of calculating the percentage of the Fbxo22-positive cancer cells to the cells present in the sample.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided is a mouth guard for endoscopes which suppresses the spread of droplets ejected from the mouth of a patient during an operation such as insertion of an endoscope into the oral cavity of the patient, does not easily expose a medical practitioner to the spread of the droplets, and has further improved convenience by means of a simple structure. This mouth guard for endoscopes is mounted on the face of the patient during endoscope operation and covers the peripheral part of the mouth, and has a main body frame part and a cover part that covers the main body frame part, wherein the main body frame part comprises: a contact frame part that makes contact with the peripheral part of the mouth of the patient; a through-hole that passes through the endoscope; and a leg part which is connected to the contact frame part by spacing the through-hole apart from the mouth of the patient to the front side of the face of the patient.

Classes IPC  ?

• A62B 18/08 - Parties constitutives des casques ou masques à gaz, p. ex. fenêtres, sangles, transmetteurs de voix, dispositifs de signalisation
• A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments
• A41D 13/11 - Masques de protection du visage, p. ex. pour utilisation chirurgicale ou pour utilisation en atmosphère polluée

Abrégé

The present invention pertains to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein in formula (1), R1to R3each independently are a predetermined amino group, a predetermined amide group, or a group represented by formula (2), and at least one among R1to R3 is a group represented by formula (2).

Classes IPC  ?

• C07H 1/00 - Procédés de préparation des dérivés du sucre
• C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 49/04 - Préparations de contraste pour rayons X

Abrégé

The present invention provides a therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM), comprising an RGMa-inhibiting substance, and a method for treating HTLV-1-associated myelopathy (HAM), comprising administering a pharmacologically effective amount of an RGMa-inhibiting substance to an HAM patient in need thereof.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

A follicular growth inducing apparatus is suitable for a surgical procedure for inducing follicular growth and is less invasive and less likely to degrade the ovarian functions. The follicular growth inducing apparatus includes an ovarian puncture needle that forms a puncture hole by puncturing an ovary in a traveling direction of ultrasound emitted from a probe in a transvaginal ultrasound device toward the ovary, for inducing growth of follicles, and an optical fiber that guides a laser beam emitted from a laser generator. The ovarian puncture needle includes a needle tube including a basal end, a shaft supported on the basal end, and a needle tip continuous with the shaft. The needle tip punctures the ovary. The optical fiber is installable in the needle tube to have a distal end of the optical fiber adjacent to the needle tip.

Classes IPC  ?

• A61B 18/28 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers le faisceau étant dirigé le long, ou à l'intérieur d'un conduit flexible, p. ex. d'une fibre optiquePièces à main à cet effet pour chauffer une sonde thermique ou un matériau absorbant thermique

Abrégé

Provided is a blood flow meter that can easily be adjusted to a predetermined surface temperature and a predetermined pressing pressure for a measurement region. A blood flow meter 1 comprises a measurement probe 10 which has an irradiation part 111 for radiating laser light, a light-receiving part 112 for receiving reflected light and scattered light, a pressure sensor 113 for measuring a pressing pressure, and a temperature sensor 114 for measuring the temperature of a tissue surface. The blood flow meter 1 preferably further comprises a reporting unit 23 for reporting whether measurement of a blood flow rate is possible, and a control unit 24 for causing the reporting unit 23 to operate so as to report that measurement of a blood flow rate is possible when the pressing pressure measured by the pressure sensor 113 is in a predetermined pressure range and the temperature of the tissue surface measured by the temperature sensor 114 is in a predetermined temperature range.

Classes IPC  ?

• A61B 5/026 - Mesure du débit sanguin

Abrégé

Provided are: a guide wire shaping mold that folds back the distal end of a guide wire to reduce damage to blood vessels and does not require any heating treatment; and a method for shaping a guide wire using the guide wire shaping mold. This guide wire shaping mold is configured to shape a guide wire having a ring-shaped distal end so as to have a reduced ring diameter and is characterized by being provided with: a wire shaping part configured such that the ring-shaped portion of the guide wire is located thereon; and a wire withdrawal path that is formed in a path shape, communicates with the wire shaping part, and is configured such that the guide wire is withdrawn in a linear direction from the proximal end.

Classes IPC  ?

• A61M 25/09 - Fils de guidage
• B21F 1/00 - Cintrage des fils métalliques autre que l'enroulementRedressage des fils métalliques

Abrégé

[Problem] To provide a motile cell selection device that can effectively select motile cells, such as sperm, that have excellent motility and an excellent morphology by performing image analysis when selecting motile cells. [Solution] A motile cell selection device 1 having a storage portion 3, a first introduction portion (cell injection channel) 5, a first introduction control portion 7, a first holding portion (cell trapping area) 9, a first extraction portion (cell recovery channel) 11, a first extraction control portion 13, a recovery portion (liquid reservoir) 15, an imaging portion 17, and a first control device 19.

Classes IPC  ?

• C12M 1/26 - Inoculateur ou échantillonneur
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12Q 1/24 - Méthodes d'échantillonnage, d'inoculation ou de développement d'un échantillonMéthodes pour isoler physiquement un micro-organisme intact

Abrégé

The present invention addresses the problem of providing a method for determining a prognosis or a method for assisting in determining a prognosis of hormone-receptor-positive cancer (e.g., ER-α-positive breast cancer, ER-α-positive endometrial cancer, etc.), and a method for evaluating susceptibility to antihormone therapy or a method for assisting in evaluating susceptibility to antihormone therapy. Specifically, the present invention is a method for determining a prognosis or a method for assisting in determining a prognosis of hormone-receptor-positive cancer, including steps (a) and (b). (a): A step for detecting Fbxo22-positive cells in a sample originating from cancer tissue. (b): A step for calculating the ratio of Fbxo22-positive cells with respect to the cells present in the sample.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• C12Q 1/06 - Détermination quantitative
• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• A61K 31/085 - Éthers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique
• A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
• A61K 31/277 - NitrilesIsonitriles ayant un cycle, p. ex. vérapamil
• A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
• A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention provides: an agent for the treatment or prevention of HTLV-1-associated myelopathy (HAM), the agent containing an RGMa inhibitor; and a HAM treatment method including the administration of a pharmacologically effective amount of an RGMa inhibitor to an HTLV-1-associated myelopathy (HAM) patient in need of the agent.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 31/12 - Antiviraux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

Provided is a follicular development inducing apparatus that is suitable for executing surgical therapy that is for the purpose of achieving follicular development induction and with which it is possible to reduce invasiveness and the risk of ovarian function deterioration. A follicular development inducing apparatus according to the present invention includes, in order to induce follicular development: an ovary piercing needle that forms a pierced hole in an ovary by piercing the ovary along a traveling direction of an ultrasonic wave emitted toward the ovary from a probe of a transvaginal ultrasonic apparatus; and an optical fiber that guides laser light emitted from a laser generator. The ovary piercing needle is constituted of a needle tube formed of a base end, a body supported by the base end, and a needle tip that is connected to the body and that pierces the ovary, and the optical fiber is placed inside the needle tube so that a distal end thereof is positioned in the vicinity of the needle tip.

Classes IPC  ?

• A61B 17/42 - Instruments ou procédés de gynécologie ou d'obstétrique
• A61B 17/34 - TrocartsAiguilles à ponction
• A61B 18/22 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par application de radiations électromagnétiques, p. ex. de micro-ondes en utilisant des lasers le faisceau étant dirigé le long, ou à l'intérieur d'un conduit flexible, p. ex. d'une fibre optiquePièces à main à cet effet
• A61N 5/067 - Thérapie par radiations utilisant un rayonnement lumineux utilisant un rayonnement laser

Abrégé

The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 31/5375 - 1,4-Oxazines, p. ex. morpholine
• A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
• A61K 31/443 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

An instrument for fixedly transplanting a living body embryo into a uterus has an instrument, for transplanting the living body embryo into the uterus, which is to be inserted into a uterus and a magnetic embryo accommodation container holding instrument (transferred embryo fixing instrument) to be attached to the living body. The instrument for transplanting the living body embryo into the uterus has an embryo accommodation container having an embryo accommodation part having an embryo insertion portion communicating with outside and a magnetic material and a shaft-shaped container transfer tool for separably holding the embryo accommodation container at its distal end portion. The magnetic container holding instrument has an attaching part to be attached to an epidermis of the living body and a magnet capable of attracting the magnetic material of the embryo accommodation container thereto.

Classes IPC  ?

• A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
• A61D 19/04 - Instruments ou procédés pour la reproduction ou la fertilisation pour la transplantation d'embryons
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61M 31/00 - Dispositifs pour l'introduction ou la rétention d'agents, p. ex. de remèdes, dans les cavités du corps

Abrégé

The purpose of the present invention is to provide a novel therapeutic or preventive agent for human T-cell leukemia virus-1-associated myelopathy (HAM), characterized by containing an anti-human CC-chemokine receptor 4 (CCR4) antibody or a fragment of the antibody as an active ingredient and by a dosage regimen of said antibody or of a fragment of the antibody. The present invention pertains to a therapeutic or preventative agent for HAM, which is characterized by containing an anti-human CCR4 antibody or a fragment of the antibody as an active ingredient and in that the antibody or fragment of the antibody is administered at a low dose.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/52 - Purines, p. ex. adénine
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
• A61K 38/13 - Cyclosporines
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette
• A61P 31/12 - Antiviraux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

A fixing instrument 10 for intrauterine implantation of vital embryo comprises: a vital embryo intrauterine implantation tool 1 which is to be inserted into the uterus; and a magnetic holder 6 for embryo housing container (an embryo implant fixing tool) which is to be attached to a living body. The vital embryo intrauterine implantation tool 1 comprises: an embryo housing part 42 provided with an embryo inserting part 44 which is communicated with outside; an embryo housing container 4 provided with a magnetic body 43; and a shaft-shaped container transfer tool 5 which detachably holds the embryo housing container 4 at the tip thereof. The magnetic holder 6 for embryo housing container is provided with: a mounting part 63 which is to be mounted to the skin surface of the living body; and a magnet 62 which is capable of attracting the magnetic body 43 in the embryo housing container 4.

Classes IPC  ?

• A61B 17/435 - Instruments ou procédés de gynécologie ou d'obstétrique pour la reproduction ou la fertilisation pour la transplantation d'embryons
• A61D 19/04 - Instruments ou procédés pour la reproduction ou la fertilisation pour la transplantation d'embryons

Abrégé

The present invention provides a pharmaceutical composition which can be used for the treatment of HTLV-1-associated myelopathy and contains an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 double inhibitor as an active ingredient. The present invention provides a pharmaceutical composition which can be used for the treatment of HTLV-1-associated myelopathy and contains a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 31/443 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention addresses the issue of providing a means to ameliorate deterioration in the quality of preimplantation embryos as a result of aging, etc. The present invention pertains to an agent for improving the quality of eggs, fertilized eggs, and/or embryos, said agent comprising a material that inhibits signal transmission from CXCL5.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
• C12N 5/0735 - Cellules souches embryonnairesCellules germinales embryonnaires
• C12N 5/075 - OocytesOogonies
• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention addresses the problem of providing a preparation effective in preventing and/or ameliorating reduction in ovarian function. Provided is an agent for preventing or ameliorating reduction in ovarian function, comprising pterostilbene.

Classes IPC  ?

• A61K 31/09 - Éthers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique ayant plusieurs liaisons éther
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs

Abrégé

2Hb).

Classes IPC  ?

• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/026 - Mesure du débit sanguin
• A61H 31/00 - Respiration artificielle par une force appliquée sur la poitrineStimulation du cœur, p. ex. massage cardiaque
• A61B 5/0295 - Mesure du débit sanguin utilisant la pléthysmographie, c.-à-d. par mesure des variations du volume d'une partie du corps induites par la circulation du sang qui traverse cette partie, p. ex. pléthysmographie par impédance

Abrégé

A collected living tissue cryopreserving tool is composed of a tissue piece holder and a resin-made accommodating bag. The tissue piece holder is composed of a plate-shaped body part including a thermally conductive plate-shaped lower member and a plate-shaped upper member and a covering sheet held by the plate-shaped body part. The tissue piece holder has a tissue piece placing part formed of a cut-out part provided on the plate-shaped upper member and a part, of an upper surface of the thermally conductive plate-shaped lower member, which is disposed at the cut-out part. The covering sheet is capable of covering the tissue piece placing part.

Classes IPC  ?

• A01N 1/00 - Conservation de corps humains ou animaux, ou de parties de ceux-ci
• A01N 1/02 - Conservation de parties vivantes
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie

Abrégé

Provided is a compound that is useful for preventing and treating glaucoma, in particular, normal-tension glaucoma. A prophylactic and/or therapeutic agent for glaucoma that comprises, as an active ingredient, a PPARα agonist selected from among (R)-2-[[3-[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propy]aminomethyl]phenoxy]butyric acid, a salt thereof, a solvate of the same and fenofibrate.

Classes IPC  ?

• A61K 31/423 - Oxazoles condensés avec des carbocycles
• A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
• A61P 27/06 - Agents antiglaucomateux ou myotiques

Abrégé

　This peptide has an NFκB inhibitory effect and is any one of the following peptides: (a) a peptide comprising any amino acid sequence from SEQ ID NOs: 1-5; (b) a peptide having an NFκB inhibitory effect and comprising any amino acid sequence from SEQ ID NOs: 1-5, wherein one or a plurality of amino acid residues having been replaced, deleted and/or added; (c) a peptide having an NFκB inhibitory effect and comprising an amino acid sequence that is at least 80% homologous with any amino acid sequence from SEQ ID NOs: 1-5; (d) a peptide in which a cell-penetrating peptide is fused with any peptide selected from (a)-(c); and (e) a peptide in which a Met residue, a MetAla residue or an Ala residue is added to the N terminal of any peptide selected from (a)-(d).

Classes IPC  ?

• C12N 15/09 - Technologie d'ADN recombinant
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 19/00 - Peptides hybrides
• C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus

Abrégé

A collected biological tissue cryopreservation tool 10 comprises a tissue fragment holder 1 and a resin-made storage bag 11. The tissue fragment holder 1 comprises a plate-shaped main body comprising a thermally-conductive plate-shaped bottom member 2 and a plate-shaped upper member 3, and a cover sheet 4 held by the plate-shaped main body. The tissue fragment holder 1 is provided with a tissue fragment placement section 5 formed of a cut-out section 32 provided to the plate-shaped upper member 3, and an upper surface of the thermally-conductive plate-shaped bottom member 2 located at the cut-out section 32. The cover sheet 4 is one that is able to cover the tissue fragment placement section 5.

Classes IPC  ?

• A01N 1/02 - Conservation de parties vivantes
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie

Abrégé

The purpose of the present invention is to provide a method for producing γδT cells with which it is possible to obtain a cell population including a large amount of γδT cells and including virtually no cells infected by human T-cell leukemia virus (HTLV) even when PBMCs derived from a person infected with HTLV are used as the cell source. A cell population including a large amount of γδT cells and including virtually no HTLV-1-infected cells is obtained by culturing after removing CD4-positive cells that express CD4 (referred to hereinafter as "CD4+ cells") and CD8-positive cells that express CD8 (referred to hereinafter as "CD8+ cells") from the PBMCs that serve as the cell source, or after removing cells that express αβT cell receptors (αβTCR) (referred to hereinafter as "αβT cells"), before growing γδT cells.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 31/04 - Agents antibactériens
• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C12N 5/078 - Cellules du sang ou du système immunitaire

Abrégé

A tool 1 for cryopreserving collected biological tissue comprises a collected tissue storage container 2, a heat-sealable storage bag 5 for storing the collected tissue storage container 2, and a container retention member 6 for retaining the collected tissue storage container 2 stored in the storage bag 5. The collected tissue storage container comprises a bottomed cylindrical container body 3 and a cover member 4 that can be attached onto the container body in an airtight state. The cover member 4 is provided with a tissue fragment placement member 41 and a seal member 48 that is provided to an inner surface of a cover body section 42 and is for sealing an opening of a transparent container body 3.

Classes IPC  ?

• C12M 1/26 - Inoculateur ou échantillonneur
• A01N 1/00 - Conservation de corps humains ou animaux, ou de parties de ceux-ci
• A01N 1/02 - Conservation de parties vivantes
• C12M 1/24 - Appareillage pour l'enzymologie ou la microbiologie en forme de tube ou de bouteille
• C12N 5/07 - Cellules animales ou tissus animaux

Abrégé

The present invention addresses the problem of providing a phototherapeutic device for metabolic bone diseases, which enables the remedy of symptoms of metabolic bone diseases. The present invention relates to a phototherapeutic device (1) for metabolic bone diseases, which is equipped with at least light source units, wherein the light source units are respectively equipped with light sources (7, 8) each capable of outputting healing light of which the main wavelength bandwidth is near-infrared light, and wherein the light source units can emit healing light output from the light sources (7, 8) onto an affected site (5).

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux

Abrégé

　In the present invention, a carbon monoxide poisoning resolving device has a light-emitting portion for emitting light within a wavelength range of 600-750 nm. This jacket emits light in a wavelength range of 600-750 nm on the inner side of the front or rear thereof. This catheter has: a main catheter body having a tip portion formed of a transparent material and including a plurality of lumens; a light-emitting portion for emitting light at a wavelength of 600-750 nm so as to be transmitted from inside a first lumen towards the outside of the main catheter body at the tip portion; a balloon for guiding the tip portion downstream in a bloodstream in an inflated state, the balloon being disposed on an outer surface of the tip portion and communicating with a second lumen; and a pressure sensor disposed on a tip of the tip portion and connected to a cable inserted in a third lumen.

Classes IPC  ?

• A61N 5/06 - Thérapie par radiations utilisant un rayonnement lumineux
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61M 25/10 - Cathéters à ballon

Abrégé

The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.

Classes IPC  ?

• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61K 35/62 - SangsuesVers, p. ex. cestodes, nématodes, vers de terre, ascarides, filaires, ankylostomes, trichines ou ténias

Abrégé

In the present invention, the amount of BARHL2 gene expression and/or the cytosine methylation frequency are used as indicators for detecting gastric cancer and for evaluating the risk the incidence of gastric cancer. Preferably, the amount of at least one among SOX17 gene and MINT25 gene expression and/or the cytosine methylation frequency are additionally used as indicators for detecting gastric cancer and for evaluating the risk the incidence of gastric cancer.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

2Hb).

Classes IPC  ?

• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/026 - Mesure du débit sanguin
• A61H 31/00 - Respiration artificielle par une force appliquée sur la poitrineStimulation du cœur, p. ex. massage cardiaque
• A61B 5/0295 - Mesure du débit sanguin utilisant la pléthysmographie, c.-à-d. par mesure des variations du volume d'une partie du corps induites par la circulation du sang qui traverse cette partie, p. ex. pléthysmographie par impédance

Abrégé

The purpose of the present invention is to provide a novel method for treating human T-lymphotropic virus 1-associated myelopathy (HAM) patients and asymptomatic HTLV-1 carriers (ACs) and a remedy therefor, said method and remedy being different from the conventional remedies. A method for treating HAM patients and ACs, said method being characterized by comprising decreasing HTLV-1 virus-infected cells using an anti-human CC-chemokine receptor 4 (CCR4) antibody, and a remedy therefor.

Classes IPC  ?

• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie

Abrégé

Provided is a sustained release carrier for drugs, which uses a silk fibroin porous body, has high strength and high sustained release efficiency for drugs, and is capable of controlling the sustained release rate for drugs. This sustained release carrier for drugs is able to be easily handled, and is gentle to the skin by having high biocompatibility. In addition, this sustained release carrier for drugs has high water retainability and is capable of efficiently holding a drug.

Classes IPC  ?

• A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
• A61K 9/70 - Bases pour bande, feuille ou filament
• A61K 38/22 - Hormones
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

This concentration-measurement device (1) measures the relative change(s) over time (ΔO2Hb and/or ΔcHb) in oxygenated hemoglobin concentration and/or total hemoglobin concentration in the head due to repeated chest compressions. Said concentration-measurement device is provided with the following: a light-input unit (21) that inputs measurement light to the head; a light-detection unit (22) that detects measurement light that has propagated through the interior of the head and generates a detection signal corresponding to the intensity of said measurement light; and a CPU (14) that obtains the relative change(s) over time (ΔO2Hb and/or ΔcHb) on the basis of the detection signal and filters out frequency components of said relative change(s) over time (ΔO2Hb and/or ΔcHb) having frequencies lower than a prescribed frequency. This results in a concentration-measurement device and concentration-measurement method that can objectively determine whether or not chest compressions are being performed appropriately.

Classes IPC  ?

• A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge

Abrégé

Disclosed is a therapeutic agent for HTLV-1-associated diseases such as HTLV-1-associated myelopathy and uveitides. Specifically disclosed is a pharmaceutical agent comprising, as an active ingredient, an RAR agonist represented by formula (I) [wherein R1 to R5 independently represent a hydrogen atom, an alkyl group, or an alkyl-substituted silyl group; X represents -CO-NH-, -NH-CO- or -CO-CH=CH-; and A represents a carboxylate-substituted aromatic group or a tropolonyl group].

Classes IPC  ?

• A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
• A61K 31/695 - Composés du silicium
• A61P 5/14 - Médicaments pour le traitement des troubles du système endocrinien des hormones thyroïdiennes, p. ex. T3, T4
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 27/02 - Agents ophtalmiques
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

In an outer needle base (14) of a bone cement injection puncture needle (10) are provided an injection port (30) for supplying bone cement to an outer needle (12), and a suction port (34) for suctioning by use of a suction device. Near the base end of the outer needle (12) is provided a side hole (22), and further, in the suction port (34) is provided a multi-way stopcock (70) as a device for maintaining reduced pressure. The bone cement injection puncture needle (10) punctures a target bone, and after an inner needle (16) is removed from the outer needle (12), the suction device is connected to the suction port (34) and gas and liquid inside the bone is suctioned, creating a negative pressure in the bone. By this means, when the bone cement is injected into the bone, said bone cement can be prevented from leaking to outside of the bone. Further, by means of putting the multi-way stopcock (70) in a closed state after suctioning, the negative pressure in the bone can be maintained.

Classes IPC  ?

• A61B 17/56 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet

Abrégé

An outer needle (12) of a bone cement injection puncture needle has first side holes (22) near the tip, and second side holes (24) near the base. When an inner needle is removed from the outer needle (12) and an inner tube is inserted into the outer needle (12) in place thereof, a reduced-pressure passage (48) is formed between the outer needle (12) and the inner tube (17). By this means, when bone cement is injected into a bone, gas and liquid in the bone pass through the reduced-pressure passage (48) and are discharged from the body, thereby preventing increased pressure in the bone. As a result, the bone cement can be prevented from leaking to outside of the bone.

Classes IPC  ?

• A61B 17/56 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet
• A61C 5/04 - Instruments pour obturer les dents naturelles; Méthodes ou instruments pour le traitement du canal du nerf de la dent
• A61F 2/28 - Os

Abrégé

Disclosed is a liquid crystal composition which contains a liquid crystal that contains a silicone compound. Specifically disclosed is a liquid crystal composition which contains a liquid crystal that contains one or more kinds of silicone surfactants, a phenyl modified silicone oil and water. The liquid crystal composition contains 5-95% by weight of the one or more kinds of silicone surfactants in total, 0.1-90% by weight of the phenyl modified silicone oil, and 0.1-90% by weight of water. Since the liquid crystal composition is capable of solubilizing a poorly soluble hydrophobic compound (for example, a hydrocarbon oil such as squalane, a fatty acid such as oleic acid or lipoic acid, and an ester oil such as cetyl isooctanoate), the liquid crystal composition is useful as a toiletry material, a cosmetic material and the like.

Classes IPC  ?

• A61K 8/06 - Émulsions
• A61K 8/89 - Polysiloxanes
• A61K 9/107 - Émulsions
• A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
• A61Q 19/10 - Préparations pour le nettoyage ou le bain
• C09K 19/02 - Substances formant des cristaux liquides caractérisées par les propriétés optiques, électriques ou physiques des constituants, en général
• C09K 19/54 - Additifs n'ayant pas de mésophase spécifique

Abrégé

Disclosed is a bone cement injection needle (100) wherein the bone cement injection needle (100) comprises: a hollow outer needle (110); an outer needle hub (120) affixed to the base end part of the outer needle (110); an inner needle (130) that can be slidably inserted into the hollow part of the outer needle (110); and an inner needle hub (140) affixed to the base end part of the inner needle (130). The outer needle (110) comprises a first side hole (113) located near the tip; a second side hole (114) located near the base end part; and a depressurization passage which connects the first side hole (113) and the second side hole (114).

Classes IPC  ?

• A61B 17/56 - Instruments ou procédés chirurgicaux pour le traitement des os ou des articulationsDispositifs spécialement adaptés à cet effet
• A61B 17/34 - TrocartsAiguilles à ponction
• A61M 3/00 - Seringues médicales, p. ex. clystèresIrrigateurs

Abrégé

A biomaterial of artificial bone-cartilage complex type can be successfully produced by contacting glycosaminoglycan, proteoglycan and collagen, which are components of a cartilage-like complex, with an artificial bone and allowing the self-organization of the preceding complex based on the preceding artificial bone.  This complex type biomaterial is a biomaterial that is usable in reconstructing a joint tissue with the integration of the bone tissue, i.e., the skeleton and the cartilage tissue side, i.e., the movable face of the joint in any bone-cartilage lesion accompanied by the degeneration or fracture of joint such as rheumatoid arthritis, degenerative joint disease, bone fracture, bone tumor and so on.

Classes IPC  ?

• A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses

Abrégé

Disclosed is a composition for external application on the skin, which has an excellent skin-whitening activity, which has reduced adverse side effects, and which comprises hydroquinone as an active ingredient. The composition for external application on the skin is characterized by containing hydroquinone or a derivative thereof mixed with a lyotropic liquid crystal.

Classes IPC  ?

• A61K 8/35 - Cétones, p. ex. quinones, benzophénone
• A61K 8/19 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés inorganiques
• A61Q 19/02 - Préparations pour les soins de la peau pour décolorer ou blanchir la peau chimiquement

Abrégé

A method for treating chronic obstructive pulmonary disease (COPD) and a stent to be used therein. The above-described stent is a stent having a hollow tube structure which is to be used in a method of treating COPD involving the step of placing the stent in a narrowed site in a peripheral bronchus (at around from the fifth bronchus to the seventh bronchus), characterized in that the outer diameter of the hollow tube ranges from 2 to 4 mm while the length of the hollow tube ranges from 10 to 20 mm. The method of treating COPD using the stent as described above is a less invasive and reversible method which never damages the pulmonary functions since a collapsed and blocked site (chalk point) of a thin bronchus is opened and the lung is saved thereby. Thus, this method is applicable not only to the case with confined tumor but also to the case with diffusely scattered tumor.

Classes IPC  ?

• A61F 2/04 - Éléments ou organes creux ou tubulaires, p. ex. vessies, trachées, bronches ou voies biliaires
• A61F 2/82 - Dispositifs maintenant le passage ou évitant l’affaissement de structures tubulaires du corps, p. ex. stents
• A61M 29/02 - Dilatateurs gonflablesDilatateurs faits de matériaux dilatables

Abrégé

Disclosed is a detection method which can detect a substance incorporated in a cell precisely and simply. A substance having an amino group or an imino group is labeled with NBD-F (4-fluoro-7-nitrobenzofurazan), and the labeled substance is allowed to be incorporated into a cell. The fluorescence emitted from the labeled substance incorporated in the cell is detected. In this manner, a substance incorporated in a cell can be observed precisely and simply. The method is useful for, for example, researching the mechanism of action of a medicinal agent, a neurotransmitter or the like.

Classes IPC  ?

• C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
• G01N 21/64 - FluorescencePhosphorescence

Abrégé

Disclosed is a novel therapeutic agent for fibromyalgia. A pharmaceutical composition comprising tizanidine as an active ingredient can be used as a therapeutic agent for fibromyalgia. The pharmaceutical composition can ameliorate a pain associated with fibromyalgia and can also ameliorate a sleep disorder, a feeling of fatigue and a depressive condition associated with fibromyalgia, and is therefore useful as a therapeutic agent for fibromyalgia.

Classes IPC  ?

• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/433 - Thiadiazoles
• A61K 35/36 - PeauSystème pileuxOnglesGlandes sébacéesCérumenÉpidermeCellules épithélialesKératinocytesCellules de LangerhansCellules ectodermiques
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61P 25/20 - HypnotiquesSédatifs
• A61P 25/22 - Anxiolytiques
• A61P 25/24 - Antidépresseurs

Abrégé

Seminal fluids are sampled from patients with infertility as the chief complaint and healthy male subjects. For each sample, the seminal fluid amount, sperm concentration, sperm mobility and sperm survival rate are measured. Also, SPMI having bound to sperm is detected with the use of anti-SPMI antibody and the amount of the bound SPMI and SPMI-binding ratio are calculated. As a result, it has been clarified that the sample group showing a certain amount of bound SPMI or more or a certain SPMI-binding ratio or higher exclusively consists of the samples obtained from the patients. Thus, it is indicated that asthenospermia can be diagnosed by determining the amount of the bound SPMI and SPMI-binding ratio.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains

Abrégé

When C60 was added to each of a synovial fibroblast, an infiltrating lymphocyte and a macrophage and the inflammatory cytokine production level was determined in each cell, the inflammatory cytokine production level was significantly reduced in each of the cells. Further, when C60 was added to an osteoclast precursor cell in the presence of an osteoclast differentiation induction factor and the osteoclast precursor cell was cultured, the differentiation of the osteoclast precursor cell into an osteoclast was inhibited by a certain concentration or higher of C60. When the influence of the addition of C60 on bone resorption was observed, it was confirmed that C60 inhibited the bone resorption by an osteoclast. It was also confirmed in vivo using a rheumatoid arthritis model animal that C60 prevented the bone resorption, bone destruction and an inflammatory condition caused by an osteoclast. C60 has an inhibitory effect on osteoclast differentiation, bone resorption and inflammatory cytokine, and therefore is effective for the treatment of an inflammation in a joint such as rheumatoid arthritis.

Classes IPC  ?

• A61K 31/015 - Hydrocarbures carbocycliques
• A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

Fibromyalgia is a disease for which development of a therapeutic agent is difficult to achieve because the cause or mechanism of onset thereof has not been elucidated yet. When salazosulfapyridine, which is a therapeutic agent for rheumatism was administered to a patient with fibromyalgia, a therapeutic effect on fibromyalgia in which a rheumatoid factor or immune disorder is not observed was unexpectedly observed, and it was effective particularly in pain relief for enthesitis. Further, it was effective in alleviation of enthesitis and also pain relief for fibromyalgia. Further, for a case in which an effect is low with the use of salazosulfapyridine alone, concomitant use of salazosulfapyridine with an adrenocorticotropic hormone or a nonsteroidal antiinflammatory agent increased the therapeutic effect of salazosulfapyridine.

Classes IPC  ?

• A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
• A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
• A61K 31/5415 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes carbocycliques, p. ex. phénothiazine, chlorpromazine, piroxicam
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C07D 213/76 - Atomes d'azote auxquels est lié un second hétéro-atome

Abrégé

The invention relates to a sample containing a gastric mucosa lavage fluid collected from a subject who has received a gastric mucus removal treatment and a method for detecting a disease-related marker using the same. By using the sample of the invention, the disease-related marker can be detected conveniently, less invasively, highly sensitively and highly accurately.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/26 - Inoculateur ou échantillonneur
• C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
• G01N 33/15 - Préparations médicinales
• C12N 15/09 - Technologie d'ADN recombinant

Abrégé

Disclosed is a method for prevention of a tumor comprising inhibiting the expression of HERC2. The inhibition of HERC2 may be achieved by the action of siRNA for HERC2 gene. As a result, HERC2 loses a function of interacting with BRCA1, whereby the activity of BRCA1 can be maintained or enhanced to induce an anti-tumor activity.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• G01N 33/15 - Préparations médicinales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique